Related Experiment Video
Updated: May 19, 2026
07:02
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
Attenuation of scopolamine-induced cognitive dysfunction by obovatol
Dong-Young Choi1, Young-Jung Lee, Sun Young Lee
1College of Pharmacy, Chungbuk National University, Cheongju 361-763, Korea.
Archives of Pharmacal Research
|August 7, 2012
Summary
Obovatol, a natural compound, improved memory in a mouse model of Alzheimer's disease by reducing beta-amyloid peptide (Aβ) accumulation and stabilizing cholinergic neurotransmission. This suggests obovatol may help prevent Alzheimer's disease progression.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Alzheimer's disease (AD) is the leading cause of dementia in older adults.
- AD pathology includes beta-amyloid peptide (Aβ) deposition, cholinergic neurodegeneration, and elevated acetylcholine esterase (AChE) activity.
- Scopolamine is used to induce memory dysfunction in research models.
Purpose of the Study:
- To investigate the effects of obovatol on scopolamine-induced memory impairment.
- To explore the underlying mechanisms of obovatol's effects on Alzheimer's disease pathology.
Main Methods:
- Obovatol was administered to mice at doses of 0.2, 0.5, and 1 mg/kg for 7 days.
- Memory function was assessed using the Morris water maze and step-through passive avoidance tests.
- Levels of Aβ generation, β-secretase activity, and AChE activity in the cortex and hippocampus were measured.
Main Results:
- Obovatol dose-dependently attenuated scopolamine-induced amnesia.
- Obovatol reduced scopolamine-induced increases in Aβ generation and β-secretase activity.
- Obovatol decreased scopolamine-induced elevation of AChE activity in the brain.
Conclusions:
- Obovatol ameliorates memory deficits associated with Alzheimer's disease pathology.
- Obovatol's therapeutic potential lies in reducing Aβ accumulation and normalizing cholinergic neurotransmission.
- Obovatol may serve as a preventative agent against Alzheimer's disease neurodegeneration.
More Related Videos
Related Concept Videos
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...